Drug Profile
GEN 0101
Alternative Names: GEN0101; HVJ-E; TSD-0014Latest Information Update: 01 Feb 2022
Price :
$50
*
At a glance
- Originator GenomIdea
- Developer GenomIdea; Ishihara Sangyo Kaisha; Osaka University Hospital; TSD Japan
- Class Antineoplastics; Viral envelope proteins
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Malignant melanoma; Mesothelioma
- No development reported Prostate cancer
Most Recent Events
- 15 Oct 2021 GenomIdea discontinues phase-II trial in Mesothelioma (Combination therapy, First-line therapy) in Japan (Parenteral) (JapicCTI194617)
- 23 Feb 2021 Phase I/II developed for Mesothelioma (Treatment-resistant) is still ongoing in Japan (SC) (UMIN000026892)
- 23 Feb 2021 Phase II development for Malignant melanoma (Combination therapy, Inoperable/Unresectable, Late-stage disease) is still ongoing in Japan (SC) (NCT03818893)